Supplement may ease the pain of sickle cell disease

July 19, 2018 by Dennis Thompson, Healthday Reporter

(HealthDay)—An FDA-approved supplement reduces episodes of severe pain in people with sickle cell disease, a new clinical trial shows.

Endari, a medicine-grade version of the dietary supplement L-glutamine, reduced sickle cell patients' number of acute pain crises by 25 percent compared with a placebo, the researchers found.

In addition, the supplement reduced hospitalizations by one-third.

"People who were on glutamine did a lot better than those patients who were on placebo in frequency of pain crises, frequency of hospitalization and duration of hospitalization," said lead researcher Dr. Yutaka Niihara. He is chairman and CEO of Emmaus Life Sciences, the maker of Endari.

Doctors now have two medications to treat , an inherited disorder that causes the body to produce abnormal red blood cells, said Dr. Caterina Minniti, director of the Sickle Cell Center for Adults at Montefiore Medical Center in New York City.

Minniti said Endari likely will be used alongside hydroxyurea, which for decades has been the only medicine available to treat sickle cell disease.

"The data shows an improvement in symptoms as far as pain, but the improvement is modest," Minniti said of the Endari trial. "In that sense, it's not revolutionary. It's additive."

Sickle cell disease affects about 100,000 people in the United States, most commonly African Americans, according to the U.S. Centers for Disease Control and Prevention.

Red blood cells affected by sickle cell disease are rigid and sticky, bent into shapes that resemble sickles or crescent moons. They break apart easily and die, causing anemia, according to the Mayo Clinic.

Acute pain crises are a major complication of sickle cell disease that often land patients in the hospital. The U.S. National Institutes of Health says that these events occur when sickle cells clump together in small blood vessels, blocking blood flow and decreasing oxygen delivery to specific parts of the body.

Niihara said that he and his colleagues suspected that L-glutamine, an amino acid, might help ward off these crises by neutralizing oxidative stress in sickle red blood cells, allowing them to return to their normal shape.

"The first patients I treated, their condition improved so much that people who used to be hospitalized every week to two weeks, they didn't have to be hospitalized for a whole three months," Niihara said.

For the new clinical trial, 230 patients were randomly assigned to receive either L-glutamine or a placebo in a 2-to-1 ratio.

People did better taking L-glutamine, either alone or with hydroxyurea, the investigators found.

"People on hydroxyurea and glutamine did better than people on hydroxyurea alone," Niihara said. "We concluded that glutamine must have an additive effect on hydroxyurea."

The U.S. Food and Drug Administration approved Endari last year for treatment of sickle cell disease, and earlier this year the U.S. Centers for Medicare and Medicaid Services agreed to cover the drug.

Private insurance companies have followed suit and also are starting to cover Endari, which is pricey, Minniti said. A year's worth of Endari costs about $40,515, compared with about $1,700 for hydroxyurea.

"Insurance most often covers it because the cost-effectiveness is there," Minniti said. "When you decrease even one episode of vaso-occlusive [acute pain] crisis in a patient with sickle cell disease, that's five to seven days of hospitalization. That's many, many thousands of dollars."

L-glutamine is a relatively common supplement used by bodybuilders and other athletes, but Minniti warned that sickle cell patients should not try to cut costs by buying the version available at health food centers.

Endari "is medicine-grade L-glutamine, so it doesn't have all the variations of what you'd buy on the shelf," Minniti said. "Patients would be very disappointed in the effectiveness of the over-the-counter supplements."

Emmaus Life Sciences paid for the clinical trial. The findings were reported in the July 19 issue of the New England Journal of Medicine.

Explore further: FDA approves first new drug in 20 years for sickle cell

More information: Yutaka Niihara, M.D., MPH, chairman and CEO, Emmaus Life Sciences, Torrance, Calif.; Caterina Minniti, M.D., director, Sickle Cell Center for Adults, Montefiore Medical Center, New York City; July 19, 2018, New England Journal of Medicine
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

The U.S. National Institutes of Health has more about sickle cell disease.

Related Stories

FDA approves first new drug in 20 years for sickle cell

July 7, 2017
The U.S. Food and Drug Administration has approved the first drug in nearly 20 years for sickle cell, an inherited disease in which abnormally shaped red blood cells can't properly carry oxygen throughout the body, which ...

A multiple drug approach to preventing sickle cell crisis

February 1, 2017
Sickle cell disease is characterized by recurrent episodes of "sickle crisis," also known as vaso-occlusive crisis, in which a patient's red blood cells change shape, clump together and block the flow of blood in small vessels ...

New drug might reduce sickle cell pain crises

December 5, 2016
(HealthDay)—An experimental drug may help reduce episodes of pain associated with sickle cell disease, a new study finds.

Novel therapy helps ease pain and suffering for sickle cell patients

September 25, 2012
Chronic, debilitating pain and potential organ failure are what approximately 100,000 sickle cell patients in the United States live with each day. Yutaka Niihara, M.D., M.P.H. - lead investigator at The Los Angeles Biomedical ...

New layers in research, treatment of sickle cell trait and stroke

June 19, 2018
Sickle cell disease increases the risk of stroke for African Americans – but recent research shows carrying the genetic trait for sickle cell doesn't.

Recommended for you

New findings cast light on lymphatic system, key player in human health

October 16, 2018
Scientists at the Oklahoma Medical Research Foundation have broken new ground in understanding how the lymphatic system works, potentially opening the door for future therapies.

Age-related increase in estrogen may cause common men's hernia

October 16, 2018
An age-related increase in estrogen may be the culprit behind inguinal hernias, a condition common among elderly men that often requires corrective surgery, according to a Northwestern Medicine study was published Oct. 15 ...

New model suggests cuffless, non-invasive blood pressure monitoring possible using pulse waves

October 16, 2018
A large team of researchers from several institutions in China and the U.S. has developed a model that suggests it should be possible to create a cuffless, non-invasive blood pressure monitor based on measuring pulse waves. ...

Discovery of inner ear function may improve diagnosis of hearing impairment

October 15, 2018
Results from a research study published in Nature Communications show how the inner ear processes speech, something that has until now been unknown. The authors of the report include researchers from Linköping University, ...

Team's study reveals hidden lives of medical biomarkers

October 12, 2018
What do medical biomarkers do on evenings and weekends, when they might be considered off the clock?

Widespread errors in 'proofreading' cause inherited blindness

October 12, 2018
Mistakes in "proofreading" the genetic code of retinal cells is the cause of a form of inherited blindness, retinitis pigmentosa (RP) caused by mutations in splicing factors.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.